Ani Pharmaceuticals stock hits 52-week high at 77.86 USD

ANI Pharmaceuticals (NASDAQ:ANIP) Inc. stock reached a 52-week high of 77.86 USD, marking a notable milestone for the company. The momentum is evident in its recent performance, with a sharp 7.95% gain just last week. This peak reflects a significant upward trend, as the stock has experienced a 22.29% increase over the past year. According to InvestingPro analysis, the company maintains strong financial health with a current ratio of 2.66, indicating solid liquidity. The rise in stock price underscores investor confidence and interest in ANI Pharmaceuticals, which has been bolstered by impressive revenue growth of 30.26% and positive analyst outlook, with price targets reaching as high as $86. This achievement highlights the company’s resilience and growth potential in the competitive pharmaceutical sector. For deeper insights into ANI Pharmaceuticals’ valuation and growth prospects, check out the comprehensive Pro Research Report available on InvestingPro, which covers what really matters for informed investment decisions.

In other recent news, ANI Pharmaceuticals reported strong earnings for the first quarter of 2025, with earnings per share of $1.70, surpassing the forecasted $1.34. The company’s revenue reached $197.1 million, marking a 43% increase compared to the previous year. In legal developments, CG Oncology won a Delaware jury trial against ANI Pharmaceuticals, freeing it from owing a 5% royalty on future sales of its investigational bladder cancer treatment. Meanwhile, ANI Pharmaceuticals faced challenges as its NEW DAY clinical trial for the Iluvien treatment in diabetic macular edema patients showed mixed results, failing to meet statistical significance in its primary endpoint. Despite this, H.C. Wainwright maintained a Buy rating for ANI Pharmaceuticals with a price target of $84.00. Additionally, ANI Pharmaceuticals announced the approval of amendments to its stock incentive and employee stock purchase plans following its Annual Meeting. These developments reflect a period of significant activity and mixed outcomes for the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.